Cancer and COVID-19 — potentially deleterious effects of delaying radiotherapy

By: Himanshu Nagar & Silvia C. Formenti. Published on April 27, 2020.

Radiotherapy can be safely delivered during the coronavirus disease 2019 (COVID-19) pandemic, often through use of hypofractionated regimens, which minimize the number of visits to treatment centres while also avoiding potentially detrimental delays in the delivery of cancer care.

Read the full article on Nature Reviews Clinical Oncology
https://www.nature.com/articles/s41571-020-0375-1

More News

Jun 25, 2022

OCCPR Leading the War Against Cancer in the Next Battlefield: Proteomics and Protegenomics

The Office of Cancer Clinical Proteomics Research (OCCPR) is the NCI's workhorse in proteomics and proteogenomics research.

Jun 22, 2022

The Next Horizon in Precision Oncology

The Next Horizon in Precision Oncology: Proteogenomics for cancer diagnosis and treatment. This Perspective which was published in Cell 2021, discussed the latest advances in genetic and molecular cancer diagnosis and opportunities for new treatment modalities.

Oct 18, 2021

In the Breast Cancer month: Breast Cancer Awareness and Education Lecture from Dr. Seza Gulec

In Breast Cancer Awareness month, our President and CEO, Dr. Seza Gulec, will be conducting a lecture to the community of Bay Harbor Islands as part of the Health Education Lecture Series. Please join us in the October Health Educational Lecture via Zoom.

May 5, 2020

How to Think About Your Cancer Care in the Time of COVID-19

Getting the news that you have cancer is overwhelming and frightening. The COVID-19 crisis adds another layer of anxiety. But know this: you can protect yourself from COVID-19 without compromising your cancer treatment.

May 5, 2020

NCI Proteomics Data Commons

The PDC was developed to advance understanding of how proteins help to shape the risk, diagnosis, development, progression, and treatment of cancer.